LeonaBio, Inc. (LONA) stock
LONANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.65−0.11 (-3.99%)
Close on Nov 18, 2026Market cap $24.97MP/E –Yield –
LeonaBio cash
Cash and short-term investments held at the end of each period.
LeonaBio's cash was $51.07M at Jun 30, 2026. For fiscal 2025 it was $88.33M, up 72.3% from the year before. The highest annual figure on record is $253.76M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.33M | +72.3% |
| FY2024 | Dec 31, 2024 | $51.28M | -65.2% |
| FY2023 | Dec 31, 2023 | $147.42M | -26.4% |
| FY2022 | Dec 31, 2022 | $200.34M | -21.0% |
| FY2021 | Dec 31, 2021 | $253.76M | +37.4% |
| FY2020 | Dec 31, 2020 | $184.68M | +8882.6% |
| FY2019 | Dec 31, 2019 | $2.06M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $51.07M | +71.2% |
| Q1 FY2026 | Mar 31, 2026 | $67.68M | +84.6% |
| Q4 FY2025 | Dec 31, 2025 | $88.33M | +72.3% |
| Q3 FY2025 | Sep 30, 2025 | $25.23M | -63.4% |
| Q2 FY2025 | Jun 30, 2025 | $29.82M | -67.5% |
| Q1 FY2025 | Mar 31, 2025 | $36.67M | -70.0% |
| Q4 FY2024 | Dec 31, 2024 | $51.28M | -65.2% |
| Q3 FY2024 | Sep 30, 2024 | $68.86M | -60.2% |
| Q2 FY2024 | Jun 30, 2024 | $91.77M | -50.7% |
| Q1 FY2024 | Mar 31, 2024 | $122.09M | -34.4% |
| Q4 FY2023 | Dec 31, 2023 | $147.42M | -26.4% |
| Q3 FY2023 | Sep 30, 2023 | $172.95M | -21.7% |
| Q2 FY2023 | Jun 30, 2023 | $186.09M | -26.3% |
| Q1 FY2023 | Mar 31, 2023 | $185.98M | -29.4% |
| Q4 FY2022 | Dec 31, 2022 | $200.34M | -21.0% |
| Q3 FY2022 | Sep 30, 2022 | $220.96M | -6.3% |
| Q2 FY2022 | Jun 30, 2022 | $252.40M | -11.4% |
| Q1 FY2022 | Mar 31, 2022 | $263.53M | -13.4% |
| Q4 FY2021 | Dec 31, 2021 | $253.76M | +37.4% |
| Q3 FY2021 | Sep 30, 2021 | $235.78M | +4.2% |
| Q2 FY2021 | Jun 30, 2021 | $284.94M | +13758.9% |
| Q1 FY2021 | Mar 31, 2021 | $304.19M | – |
| Q4 FY2020 | Dec 31, 2020 | $184.68M | – |
| Q3 FY2020 | Sep 30, 2020 | $226.27M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.06M | – |
See a number that looks wrong?